Chapter 16

Molecular Targeted Therapies for Hematologic Malignancies

Alexandre Nonino

Abstract

Protein kinase inhibition has become a promising strategy for cancer therapy since the successful results obtained with Imatinib in the treatment of Chronic Myeloid Leukemia. Several other compounds that target specific kinases are now in clinical development for myeloid and lymphoid neoplasms. In this chapter we discuss the role of kinase dysregulation in hematologic malignancies and the development of inhibitors for these targets.

Total Pages: 218-227 (10)

Purchase Chapter  Book Details